Germline deletion of the miR-1792 cluster causes skeletal and growth defects in humans

Abstract

MicroRNAs (miRNAs) are key regulators of gene expression in animals and plants. Studies in a variety of model organisms show that miRNAs modulate developmental processes. To our knowledge, the only hereditary condition known to be caused by a miRNA is a form of adult-onset non-syndromic deafness1, and no miRNA mutation has yet been found to be responsible for any developmental defect in humans. Here we report the identification of germline hemizygous deletions of MIR17HG, encoding the miR-1792 polycistronic miRNA cluster, in individuals with microcephaly, short stature and digital abnormalities. We demonstrate that haploinsufficiency of miR-1792 is responsible for these developmental abnormalities by showing that mice harboring targeted deletion of the miR-1792 cluster phenocopy several key features of the affected humans. These findings identify a regulatory function for miR-1792 in growth and skeletal development and represent the first example of an miRNA gene responsible for a syndromic developmental defect in humans.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Clinical features of individuals with 13q31.3 deletions.
Figure 2: Mapping 13q31.3 microdeletions in individuals with Feingold syndrome.
Figure 3: miR-1792Δ/+ mice display features of Feingold syndrome.
Figure 4: Widespread skeletal defects in E18.5 miR-1792Δ/Δ embryos.

References

  1. 1

    Mencía, A. et al. Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss. Nat. Genet. 41, 609–613 (2009).

  2. 2

    Fontana, L. et al. Antagomir-17–5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE 3, e2236 (2008).

  3. 3

    Hayashita, Y. et al. A polycistronic microRNA cluster, miR-17–92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 65, 9628–9632 (2005).

  4. 4

    He, L. et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828–833 (2005).

  5. 5

    Mu, P. et al. Genetic dissection of the miR-1792 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 23, 2806–2811 (2009).

  6. 6

    Northcott, P.A. et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog–driven medulloblastomas and induced by N-myc in sonic hedgehog–treated cerebellar neural precursors. Cancer Res. 69, 3249–3255 (2009).

  7. 7

    Olive, V. et al. miR-19 is a key oncogenic component of mir-17–92. Genes Dev. 23, 2839–2849 (2009).

  8. 8

    Ota, A. et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 64, 3087–3095 (2004).

  9. 9

    Tagawa, H. & Seto, M. A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia 19, 2013–2016 (2005).

  10. 10

    Uziel, T. et al. The miR-1792 cluster collaborates with the sonic hedgehog pathway in medulloblastoma. Proc. Natl. Acad. Sci. USA 106, 2812–2817 (2009).

  11. 11

    Ventura, A. et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132, 875–886 (2008).

  12. 12

    Celli, J., van Bokhoven, H. & Brunner, H.G. Feingold syndrome: clinical review and genetic mapping. Am. J. Med. Genet. A. 122A, 294–300 (2003).

  13. 13

    Feingold, M., Hall, B.D., Lacassie, Y. & Martinez-Frias, M.L. Syndrome of microcephaly, facial and hand abnormalities, tracheoesophageal fistula, duodenal atresia, and developmental delay. Am. J. Med. Genet. 69, 245–249 (1997).

  14. 14

    van Bokhoven, H. et al. MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome. Nat. Genet. 37, 465–467 (2005).

  15. 15

    Marcelis, C.L. et al. Genotype-phenotype correlations in MYCN-related Feingold syndrome. Hum. Mutat. 29, 1125–1132 (2008).

  16. 16

    Firth, H.V. et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. Am. J. Hum. Genet. 84, 524–533 (2009).

  17. 17

    Morales, J.A., Mendizabal, A.P., Vasquez, A.I., Figuera, L.E. & Gonzalez-Garcia, J.R. Interstitial deletion of 13q22→q31: case report and review of the literature. Clin. Dysmorphol. 15, 139–143 (2006).

  18. 18

    Quélin, C. et al. Twelve new patients with 13q deletion syndrome: genotype-phenotype analyses in progress. Eur. J. Med. Genet. 52, 41–46 (2009).

  19. 19

    Iafrate, A.J. et al. Detection of large-scale variation in the human genome. Nat. Genet. 36, 949–951 (2004).

  20. 20

    Kidd, J.M. et al. Mapping and sequencing of structural variation from eight human genomes. Nature 453, 56–64 (2008).

  21. 21

    O'Donnell, K.A., Wentzel, E.A., Zeller, K.I., Dang, C.V. & Mendell, J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839–843 (2005).

  22. 22

    Schulte, J.H. et al. MYCN regulates oncogenic microRNAs in neuroblastoma. Int. J. Cancer 122, 699–704 (2008).

  23. 23

    Lovén, J. et al. MYCN-regulated microRNAs repress estrogen receptor-α (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc. Natl. Acad. Sci. USA 107, 1553–1558 (2010).

  24. 24

    Chen, X. et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 133, 1106–1117 (2008).

  25. 25

    Dews, M. et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat. Genet. 38, 1060–1065 (2006).

  26. 26

    Nagy, A. et al. Dissecting the role of N-myc in development using a single targeting vector to generate a series of alleles. Curr. Biol. 8, 661–664 (1998).

  27. 27

    Moens, C.B., Auerbach, A.B., Conlon, R.A., Joyner, A.L. & Rossant, J. A targeted mutation reveals a role for N-myc in branching morphogenesis in the embryonic mouse lung. Genes Dev. 6, 691–704 (1992).

  28. 28

    Ota, S., Zhou, Z.Q., Keene, D.R., Knoepfler, P. & Hurlin, P.J. Activities of N-Myc in the developing limb link control of skeletal size with digit separation. Development 134, 1583–1592 (2007).

  29. 29

    Stanton, B.R., Perkins, A.S., Tessarollo, L., Sassoon, D.A. & Parada, L.F. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev. 6, 2235–2247 (1992).

  30. 30

    Sawai, S. et al. Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse. Development 117, 1445–1455 (1993).

  31. 31

    Mestdagh, P. et al. The miR-17–92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol. Cell 40, 762–773 (2010).

  32. 32

    Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 103, 2257–2261 (2006).

  33. 33

    Dews, M. et al. The myc-miR-1792 axis blunts TGF-β signaling and production of multiple TGF-β-dependent antiangiogenic factors. Cancer Res. 70, 8233–8246 (2010).

  34. 34

    Cognet, M. et al. Dissection of the MYCN locus in Feingold syndrome and isolated oesophageal atresia. Eur. J. Hum. Genet. 19, 602–606 (2011).

  35. 35

    Masurel-Paulet, A. et al. Delineation of 15q13.3 microdeletions. Clin. Genet. 78, 149–161 (2010).

Download references

Acknowledgements

We are thankful to the subjects and their referent doctors for their active participation in this study. We are also particularly thankful to P. Hurlin for generously providing forelimbs of Mycn conditional knockout mouse embryos. This work was supported by grants from the Agence Nationale de la Recherche (ANR grant EvoDevoMut), the Foundation pour la Recherche Médicale (FRM), the Institut National du Cancer-Direction de l'Hospitalisation et de l'Organisation des soins (INCa-DHOS), and the Institut National du Cancer. Work in the laboratory of A.V. was funded by US National Institutes of Health (NIH)-National Cancer Institute (NCI) grant R01CA149707, a Sidney Kimmel Award and a Geoffrey Beene Research Grant. E.Y. is a recipient of the NIH Molecular and Cellular Biology T32 training grant. We thank L. Selleri for her expertise in the phenotypic analysis of miR-1792–mutant mice skeletons, L. Legeai-Mallet, A. Pelet and P. Ogrodowski for helpful discussion and technical advice and J. Hollenstein for editing the manuscript.

Author information

L.d.P., P.C., S.C. and M.O. performed subject-related experiments. E.Y. performed the analysis of miR-1792 mutant mice, the ChIP experiments and determined miR-1792 expression in subjects. J.A.V. determined miR-1792 expression in mouse embryos. J.A. and A.V. designed and supervised the project and wrote the manuscript. A.M., M.V., S.L., L.d.P., E.Y. and A.H.-C. provided critical input into project development and manuscript preparation. All other coauthors identified subjects with Feingold syndrome and performed related clinical and laboratory studies (L.F., V.D., A.V.H., D.G., A.G. and S.M.).

Correspondence to Andrea Ventura or Jeanne Amiel.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–6, Supplementary Tables 1–3 and Supplementary Note. (PDF 2159 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

de Pontual, L., Yao, E., Callier, P. et al. Germline deletion of the miR-1792 cluster causes skeletal and growth defects in humans. Nat Genet 43, 1026–1030 (2011) doi:10.1038/ng.915

Download citation

Further reading